A Non-Interventional Study on Type 2 Diabetes Mellitus Patient's Characteristics and Management by General Practitioners and Endocrinologists in the Russian Population (THESEUS)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms THESEUS
- Sponsors AstraZeneca
- 27 Dec 2018 Planned End Date changed from 16 Dec 2018 to 30 Jun 2019.
- 27 Dec 2018 Planned primary completion date changed from 16 Dec 2018 to 30 Jun 2019.
- 01 Oct 2018 Status changed from recruiting to active, no longer recruiting.